Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer;Erratum to: Targeting NAD(P)H:Quinone Oxidoreductase (NQO1) in Pancreatic Cancer (10.1002/mc.20107)

Molecular Carcinogenesis

Volumn 56, Issue 7, 2017, Pages 1825-1834

  Lewis, Anne M ^a   Ough, Matthew ^a   Du, Juan ^a   Tsao, Ming Sound ^c   Oberley, Larry W ^a   Cullen, Joseph J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

antioxidants; NAD(P)H:quinone oxidoreductase; pancreatic cancer; streptonigrin; Pancreatic cancer; Streptonigrin; Tissue microarray

Indexed keywords

ERRATUM; ERROR;

EID: 85021143774     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20107     Document Type: Article

References (38)

1. Powis G, Svingen BA, Appel P. Quinone-stimulated superoxide formation by subcellular fractions, isolated hepato-cytes, and other cells. Mol Pharmacol 1981;20:387–394.
2. Chesis PL, Levin DE, Smith MT, Ernster L, Ames BN. Mutagenicity of quinones: Pathways of metabolic activation and detoxification. Proc Natl Acad Sci USA 1984;81:1696–1700.
3. Lind C, Hochstein P, Ernster L. DT-Diaphorase as a quinone reductase: A cellular control device against semiquinoneand superoxide radical formation. Arch Biochem Biophys 1982;216:178–185.
4. Thor H, Smith MT, Hartxell P, Bellomo G, Jewell SA, Orrenius S. The metabolism of menadione (2-methyl-1,4-naphtho-quinone) by isolated hepatocytes. A study of the implication of oxidative stress in intact cells. J Biol Chem 1982;257:12419–12425.
5. Siegel D, Ross D. Immunodetection of NAD(P)H: Quinone oxidoreductase 1 (NQO1) in human tissues. Free Rad Biol Med 2000;29:246–353.
6. Huggins C, Fukunishi R. Induced protection of adrenal cortex against 7, 12- dimethylbenz(alpha)anthracene: Influence of ethionine: Induction of menadione reductase: Incorporation of thymidine H3. J Exp Med 1964;119:923–942.
7. Strassburg A, Strassburg CP, Manns MP, Tukey RH. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol 2002;61:320–325.
8. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Can Res 2003;63:2649–2657.
9. Cullen JJ, Hinkhouse MM, Grady M, et al. Dicumarol inhibition of NAD(P)H:quinine oxidoreductase (NQO1) induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Can Res 2003;63:5513–5520.
10. Cone R, Hasan SK, Lown JW, Morgan AR. The mechanism of the degradation of DNA by streptonigrin. Can J Biochem 1976;54:219–223.
11. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao M-S. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts by transfection with the E6E7 gene of human papilloma virus 16. Am J Patho 1996;148:1763–1770.
12. Ouyang H, Mou L-J, Luk C, Liu N, Squire J, Tsao M-S. Paradiploid human pancreatic duct epithelial cell lines with near normal phenotype. Am J Pathol 2000;157:1623–1631.
13. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasm: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579–586.
14. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969–2972.
15. Al-Aynati MM, Radulovich N, Riddell RH, Tsao MS. Epithelialcadherin and β-Catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res 2004;10:1235–1240.
16. Lam EWN, Hammad HM, Zwack R, et al. Immunolocalization and adenoviral vector-mediated manganese superoxide dismutase gene transfer to experimental oral tumors. J Dent Res 2000;79:1410–1417.
17. Belinsky M, Jaiswal AK. NADPH:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993;12:103–117.
18. Winski SL, Swann E, Hargreaves RHJ, et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinines. Biochem Pharm 2001;61:1509–1516.
19. Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler F, Ross D. Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones:quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 1995;48:499–504.
20. Rao KV, Biemann K, Woodward RB. The structure of streptonigrin. J Am Chem Soc 1963;85:2532–2533.
21. Oleson JJ, Calderella LA, Mjos KJ, Reith AR, Thie RS, Toplin I. The effects of streptonigrin on experimental tumors. Antibiot Chemother 1961;11:158–164.
22. Reilly HC, Sigiura K. An antitumor spectrum of streptonigrin. Antibiot Chemother 1961;11:174–177.
23. Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW, Ross D. Metabolism of bioreductive antitumor compounds. Cancer Res 1994;54:3196–3201.
24. Mizuno NS. Effects of streptonigrin on nucleic acid metabolism of tissue culture cells. Biochem Biophys Acta 1965;108:394–403.
25. Levine M, Borthwick M. The action of streptonigrin on bacterial DNA metabolism and on induction of phage production in lysogenic bacteria. Virology 1963;21:568–574.
26. White HL, White JR. Lethal action and metabolic effects of streptonigrin on Escherichia coli. Mol Pharmacol 1968;4:549–565.
27. Lown JW, Sim SK. Studies related to anti-tumor antibiotics. Part VIII. Cleavage of DNA by streptonigrin analogues and the relationship to antineoplastic activity. Can J Biochem 1976;54:446–452.
28. Beall HD, Liu Y, Siegel D, Bolton EM, Gibson NW, Ross D. Role of NAD(P)H:Quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrir. Biochem Pharm 1996;51:645–652.
29. Llopis J, Ernster L, Cadenas E. Effect of glutathione on th redox transitions of naphthohydroquinone derivatives form ed during DT-diaphorase catalysis. Free Radical Res Commu 1990;8:271–285.
30. Buettner GR. The pecking order of free radicals and ant oxidants: Lipid peroxidation, alpha-tocopherol, and ascor bate. Arch Biochem Biophys 1993;300:535–543.
31. Dinkova-Kostova AT, Talalay P. Persuasive evidence tha quinone reductase type 1 (DT-Diaphorase) protects cell against the toxicity of electrophiles and reactive forms of oxygen. Free Rad Biol Med 2000;29:231–240.
32. Lewis A, Ough M, Li L, et al. Treatment of pancreatic cance cells with dicumarol induces cytotoxicity and oxidative stress. Clin Can Res 2004;10:4550–4558.
33. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13 560 patient with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study. Br J Surg 1995;82:111–115.
34. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004 CA. Cancer J Clin 2004;54:8–29.
35. Geer RJ, Brennan MF. Prognostic indicators for survival afte resection of pancreatic adenocarcinoma. Am J Surg 1993 165:68-72. pancreaticoduodenectomy. Surgery 1999;126:178–183.
36. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreati cancer: A report of treatment and survival trends for 100 31 patients diagnosed from 1985-1995, using the Nation; Cancer Database. J Am Coll Surg 1999;189:1–7.
37. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarc noma of the pancreas- 616 patients: Results, outcomes, an prognostic indicators. J Gastrointest Surg 2000;4:567–579.
38. Neoptolemos JP, Stocken DD, Friess H, et al. A randomize trial of chemoradiotherapy and chemotherapy after resectio of pancreatic cancer. N Engl J Med 2004;350:1200–1210.